Literature DB >> 21142910

Biomarker-adaptive clinical trial designs.

Boris Freidlin, Edward L Korn.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 21142910     DOI： 10.2217/pgs.10.153

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  12 in total

1.  Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints.

Authors:  Eric A Macklin; Deborah Blacker; Bradley T Hyman; Rebecca A Betensky
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 2.  Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.

Authors:  Afsaneh Shirani; Darin T Okuda; Olaf Stüve
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Authors:  Yaacov Richard Lawrence; Bhadrasain Vikram; James J Dignam; Arnab Chakravarti; Mitchell Machtay; Boris Freidlin; Naoko Takebe; Walter J Curran; Soren M Bentzen; Paul Okunieff; C Norman Coleman; Adam P Dicker
Journal:  J Natl Cancer Inst       Date:  2012-12-10       Impact factor: 13.506

Review 4.  Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Ruwanthi Kolamunnage-Dona; Andrea L Jorgensen
Journal:  J Pers Med       Date:  2017-01-25

Review 5.  Cancer biomarkers: selecting the right drug for the right patient.

Authors:  Gary J Kelloff; Caroline C Sigman
Journal:  Nat Rev Drug Discov       Date:  2012-02-10       Impact factor: 84.694

6.  The Challenge for Development of Valuable Immuno-oncology Biomarkers.

Authors:  Janice M Mehnert; Arta M Monjazeb; Johanna M T Beerthuijzen; Deborah Collyar; Larry Rubinstein; Lyndsay N Harris
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

7.  Adjusting for misclassification in a stratified biomarker clinical trial.

Authors:  Chunling Liu; Aiyi Liu; Jiang Hu; Vivian Yuan; Susan Halabi
Journal:  Stat Med       Date:  2014-04-14       Impact factor: 2.373

Review 8.  Cancer biology as revealed by the research autopsy.

Authors:  Christine A Iacobuzio-Donahue; Chelsea Michael; Priscilla Baez; Rajya Kappagantula; Jody E Hooper; Travis J Hollman
Journal:  Nat Rev Cancer       Date:  2019-09-13       Impact factor: 60.716

Review 9.  Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Andrea L Jorgensen; Ruwanthi Kolamunnage-Dona
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

10.  Evaluating many treatments and biomarkers in oncology: a new design.

Authors:  Richard Kaplan; Timothy Maughan; Angela Crook; David Fisher; Richard Wilson; Louise Brown; Mahesh Parmar
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.